{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=STA9090", "query": { "intervention": "STA9090" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 33, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=STA9090&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T13:08:23.538Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02008877", "title": "SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Peripheral Nerve Sheath Tumors (MPNST)", "Sarcoma" ], "interventions": [ { "name": "ganetespib", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarcoma Alliance for Research through Collaboration", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 20, "start_date": "2013-12", "completion_date": "2018-07", "has_results": true, "last_update_posted_date": "2019-05-15", "last_synced_at": "2026-09-09T13:08:23.538Z", "location_count": 7, "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Iowa City, Iowa + 4 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02008877" }, { "nct_id": "NCT01348126", "title": "Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer Stage IIIB", "Non-small Cell Lung Cancer Stage IV", "Non-small Cell Lung Cancer Metastatic" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Combination of ganetespib and docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synta Pharmaceuticals Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 385, "start_date": "2011-05", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2015-11-05", "last_synced_at": "2026-09-09T13:08:23.538Z", "location_count": 8, "location_summary": "Tucson, Arizona • Santa Monica, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01348126" }, { "nct_id": "NCT01031225", "title": "A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "STA 9090", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synta Pharmaceuticals Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2009-11", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2014-09-19", "last_synced_at": "2026-09-09T13:08:23.538Z", "location_count": 21, "location_summary": "Tucson, Arizona • Hot Springs, Arkansas • Duarte, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01031225" }, { "nct_id": "NCT01167114", "title": "STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophagogastric Cancer" ], "interventions": [ { "name": "STA-9090", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2010-08", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2023-11-02", "last_synced_at": "2026-09-09T13:08:23.538Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01167114" }, { "nct_id": "NCT01200238", "title": "STA-9090(Ganetespib) in Metastatic Ocular Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ocular Melanoma" ], "interventions": [ { "name": "STA-9090", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2010-09-17", "completion_date": "2016-11-11", "has_results": true, "last_update_posted_date": "2018-10-18", "last_synced_at": "2026-09-09T13:08:23.538Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01200238" }, { "nct_id": "NCT01227018", "title": "PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Pancreas", "Recurrent Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "STA-9090", "type": "DRUG" }, { "name": "Radiologic imaging", "type": "RADIATION" }, { "name": "blood draw", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2010-12", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2014-07-23", "last_synced_at": "2026-09-09T13:08:23.538Z", "location_count": 2, "location_summary": "Memphis, Tennessee • Nashville, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01227018" }, { "nct_id": "NCT02192541", "title": "Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Ziv-Aflibercept", "type": "DRUG" }, { "name": "Ganetespib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 5, "start_date": "2014-12-02", "completion_date": "2016-02-25", "has_results": true, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-09-09T13:08:23.538Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02192541" }, { "nct_id": "NCT02389751", "title": "Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastroesophageal Junction Adenocarcinoma", "Malignant Neoplasm of the Cervical Esophagus", "Malignant Neoplasm of the Thoracic Esophagus", "Stage IIA Esophageal Cancer AJCC v7", "Stage IIB Esophageal Cancer AJCC v7", "Stage IIIA Esophageal Cancer AJCC v7", "Stage IIIB Esophageal Cancer AJCC v7", "Stage IIIC Esophageal Cancer AJCC v7" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ganetespib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2015-04-10", "completion_date": "2019-07-16", "has_results": false, "last_update_posted_date": "2019-07-24", "last_synced_at": "2026-09-09T13:08:23.538Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02389751" }, { "nct_id": "NCT01042379", "title": "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Breast Cancer", "Breast Tumors", "Angiosarcoma", "TNBC - Triple-Negative Breast Cancer", "HER2-positive Breast Cancer", "HER2-negative Breast Cancer", "Hormone Receptor Positive Tumor", "Hormone Receptor Negative Tumor", "Early-stage Breast Cancer", "Locally Advanced Breast Cancer" ], "interventions": [ { "name": "Standard Therapy", "type": "DRUG" }, { "name": "AMG 386 with or without Trastuzumab", "type": "DRUG" }, { "name": "AMG 479 (Ganitumab) plus Metformin", "type": "DRUG" }, { "name": "MK-2206 with or without Trastuzumab", "type": "DRUG" }, { "name": "AMG 386 and Trastuzumab", "type": "DRUG" }, { "name": "T-DM1 and Pertuzumab", "type": "DRUG" }, { "name": "Pertuzumab and Trastuzumab", "type": "DRUG" }, { "name": "Ganetespib", "type": "DRUG" }, { "name": "ABT-888", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "PLX3397", "type": "DRUG" }, { "name": "Pembrolizumab - 4 cycle", "type": "DRUG" }, { "name": "Talazoparib plus Irinotecan", "type": "DRUG" }, { "name": "Patritumab and Trastuzumab", "type": "DRUG" }, { "name": "Pembrolizumab - 8 cycle", "type": "DRUG" }, { "name": "SGN-LIV1A", "type": "DRUG" }, { "name": "Durvalumab plus Olaparib", "type": "DRUG" }, { "name": "SD-101 + Pembrolizumab", "type": "DRUG" }, { "name": "Tucatinib plus trastuzumab and pertuzumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Cemiplimab plus REGN3767", "type": "DRUG" }, { "name": "Trilaciclib with or without trastuzumab + pertuzumab", "type": "DRUG" }, { "name": "SYD985 ([vic-]trastuzumab duocarmazine)", "type": "DRUG" }, { "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab", "type": "DRUG" }, { "name": "Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab", "type": "DRUG" }, { "name": "Amcenestrant", "type": "DRUG" }, { "name": "Amcenestrant + Abemaciclib", "type": "DRUG" }, { "name": "Amcenestrant + Letrozole", "type": "DRUG" }, { "name": "ARX788", "type": "DRUG" }, { "name": "ARX788 + Cemiplimab", "type": "DRUG" }, { "name": "VV1 + Cemiplimab", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" }, { "name": "Datopotamab deruxtecan + Durvalumab", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Lasofoxifene", "type": "DRUG" }, { "name": "Z-endoxifen", "type": "DRUG" }, { "name": "ARV-471", "type": "DRUG" }, { "name": "ARV-471 + Letrozole", "type": "DRUG" }, { "name": "ARV-471 + Abemaciclib", "type": "DRUG" }, { "name": "Endoxifen + Abemaciclib", "type": "DRUG" }, { "name": "Rilvegostomig + TDXd", "type": "DRUG" }, { "name": "Dan222 + Niraparib", "type": "DRUG" }, { "name": "Sarilumab + Cemiplimab + Paclitaxel", "type": "DRUG" }, { "name": "GSK 5733584", "type": "DRUG" }, { "name": "GSK 5733584 + Dostarlimab", "type": "DRUG" }, { "name": "Ivonescimab (20mg/kg Q3W)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2010-03-01", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-09T13:08:23.538Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Davis", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01042379" }, { "nct_id": "NCT02334319", "title": "Ganetespib Window of Opportunity Study in Head and Neck Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage I Hypopharyngeal Squamous Cell Carcinoma", "Stage I Laryngeal Squamous Cell Carcinoma", "Stage I Oral Cavity Squamous Cell Carcinoma", "Stage I Oropharyngeal Squamous Cell Carcinoma", "Stage II Hypopharyngeal Squamous Cell Carcinoma", "Stage II Laryngeal Squamous Cell Carcinoma", "Stage II Oral Cavity Squamous Cell Carcinoma", "Stage II Oropharyngeal Squamous Cell Carcinoma", "Stage III Hypopharyngeal Squamous Cell Carcinoma", "Stage III Laryngeal Squamous Cell Carcinoma", "Stage III Oral Cavity Squamous Cell Carcinoma", "Stage III Oropharyngeal Squamous Cell Carcinoma", "Stage IVA Hypopharyngeal Squamous Cell Carcinoma", "Stage IVA Laryngeal Squamous Cell Carcinoma", "Stage IVA Oral Cavity Squamous Cell Carcinoma", "Stage IVA Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Ganetespib", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "19 Years to 79 Years" }, "enrollment_count": 3, "start_date": "2014-12", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-07-26", "last_synced_at": "2026-09-09T13:08:23.538Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02334319" } ] }